{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:21:24Z","timestamp":1788409284819,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the real\u2010world clinical use of maintenance bacillus Calmette\u2010Gu\u00e9rin (mBCG) therapy for high\u2010risk non\u2010muscle\u2010invasive bladder cancer (HR\u2010NMIBC) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This multicentre, retrospective, observational study included patients who received intravesical mBCG for HR\u2010NMIBC following transurethral resection of bladder tumours between 2000 and 2023, and who were included in the Japan Urological Oncology Group registry database. Assessments included real\u2010world mBCG treatment duration, the completion rate of planned treatment, reasons for treatment discontinuation and mBCG effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 886 patients (median [interquartile range] age 71.0 [65.0\u201377.0] years; male, 83.5%). The median (interquartile range) treatment duration was 11 (6\u201317) months, with 43.8% of patients completing the physician\u2010determined planned treatment duration. The percentage of patients with mBCG treatment duration of 3, 6, 12, 18 and 24\u2009months was 21.6%, 21.8%, 31.3%, 7.6% and 9.2%, respectively. Adverse events were the most common reason for mBCG discontinuation (49.1%). The recurrence\u2010free survival, progression\u2010free survival, overall survival and bladder preservation durations were numerically shorter in patients treated for 3\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first comprehensive study of the real\u2010world use of mBCG treatment for HR\u2010NMIBC in Japan found diverse treatment patterns, with approximately 40% of patients receiving mBCG for &lt;1\u00a0year, which is shorter than the guideline\u2010recommended treatment duration. The results underscore the need for early and sustained adverse event management, and provide valuable reference data for optimising mBCG therapy in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bco2.70091","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:14:07Z","timestamp":1759367647000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real\u2010world use of maintenance bacillus Calmette\u2010Gu\u00e9rin therapy in patients with non\u2010muscle\u2010invasive bladder cancer in Japan: ASUKA study"],"prefix":"10.1002","volume":"6","author":[{"given":"Makito","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Urology Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Tokumaru","sequence":"additional","affiliation":[{"name":"Oncology Medical, AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Oi","sequence":"additional","affiliation":[{"name":"Oncology Medical, AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Oncology Medical, AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-2464","authenticated-orcid":false,"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Nara Medical University  Nara Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine University of Toyama  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine University of Toyama  Toyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10]]},"reference":[{"issue":"2","key":"e_1_2_9_2_1","first-page":"43","article-title":"Non\u2010muscle\u2010invasive bladder cancer: Overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","volume":"22","author":"Matulewicz RS","year":"2020","journal-title":"Rev Urol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000593"},{"key":"e_1_2_9_4_1","volume-title":"Clinical Practice Guideline for Bladder Cancer 2019 Edition","author":"Japanese Urological Association","year":"2019"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_9_7_1","unstructured":"European Association of Urology.Non\u2010muscle\u2010invasive bladder cancer. Accessed March 2 2025.https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S341896"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0817"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0271"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS500"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589"},{"key":"e_1_2_9_13_1","unstructured":"AstraZeneca.Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease\u2010free survival for high\u2010risk non\u2010muscle\u2010invasive bladder cancer in POTOMAC phase III trial. News release. Accessed July 11 2025.https:\/\/tinyurl.com\/y6phhzhu"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03738-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07966-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.12.039"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09891.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02584.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13167"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03908-x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14065"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.124208"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01988-8"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02486.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.12.024"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.04.012"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.717"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1326889"},{"key":"e_1_2_9_31_1","unstructured":"Cleveland Clinic.Bacillus Calmette\u2010Guerin (BCG) treatment. Accessed May 7 2025.https:\/\/my.clevelandclinic.org\/health\/treatments\/17908-bacillus-calmette-guerin-bcg-treatment"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:47:17Z","timestamp":1764719237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.70091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/bco2.70091"],"URL":"https:\/\/doi.org\/10.1002\/bco2.70091","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70091"}}